Patents by Inventor Keiko Makita

Keiko Makita has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220281899
    Abstract: Provided are the following compound and a fluorescently labeled biological substance having this fluorescent compound. X represents CR7 or N. R1 to R7, Q1, and Q2 represent a hydrogen atom, a halogen atom, a cyano group, or a group represented by Formula (A), and adjacent substituents may form a ring structure. However, at least one of R3, R4, R7, Q1, or Q2 contains, as a hydrophilic group, at least one of a carboxy group or a salt thereof, a sulfo group or a salt thereof, a phosphono group or a salt thereof, an onio group, or a polyamino acid residue, where at least one of Q1 or Q2 represents an alkyl group.
    Type: Application
    Filed: May 11, 2022
    Publication date: September 8, 2022
    Applicant: FUJIFILM Corporation
    Inventors: Hiyoku NAKATA, Masato SAKAKIBARA, Akihiro ASAKURA, Keiko MAKITA
  • Patent number: 10987349
    Abstract: It is an object of the present invention to provide an antitumor agent, which is further excellent as a treatment agent used in the prevention and/or therapy of tumor associated with a bromodomain, and also to provide a bromodomain inhibitor, which is useful as a treatment agent for diseases or states associated with a bromodomain. An antitumor agent and a bromodomain inhibitor, comprising a compound represented by the following formula, have an excellent bromodomain inhibitory activity and are useful as treatment agents in the prevention and/or therapy of tumor associated with a bromodomain, and the like: wherein R1 represents a C1-6 alkyl group, etc.; R2 represents a hydrogen atom, etc.; R3 represents a halogen atom, etc.; Z1, Z2 and Z3 each represent CH, etc.; X1 represents CONH, etc.; Ring A represents a phenyl group, etc.; R4 represents a halogen atom, etc.; and m represents an integer from 0 to 5.
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: April 27, 2021
    Assignees: FUJIFILM Corporation, FUJIFILM Toyama Chemical Co., Ltd., NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY
    Inventors: Keiko Makita, Kazunori Saeki, Tadashi Tanaka, Masataka Fujino, Tohru Natsume, Kentaro Furuya
  • Publication number: 20210088526
    Abstract: Provided are any one of the following fluorescent compounds and a fluorescent labeled biological substance having this fluorescent compound. X represents CR5 or N, and R1 to R7, Q1, Q2, L1, and L2 each represent a specific group. a ring ?1 and a ring ?2 are a 5- to 8-membered ring, At least one of R1 to R7, L1, L2, Q1, or Q2 has a specific hydrophilic group. However, in a case where the ring ?1 and the ring ?2 are a 6-membered ring, and L1 and L2 are an arylene group, R5 is not an aryl group substituted with a linear alkyl group having 18 or more carbon atoms. In addition to the regulation of the ring ?1, the ring ?2, L1, and L2, in a case where R5 has a substituent having a dipyrromethene boron complex structure, the dipyrromethene boron complex structure has a structure in which a dipyrromethene skeleton is coordinately bonded to a boron atom in the tridentate or tetradentate coordination.
    Type: Application
    Filed: November 27, 2020
    Publication date: March 25, 2021
    Applicant: FUJIFILM Corporation
    Inventors: Hiyoku NAKATA, Kousuke WATANABE, Akihiro ASAKURA, Keiko MAKITA, Yoshinori KANAZAWA, Kazuhei KANEKO
  • Publication number: 20190314360
    Abstract: It is an object of the present invention to provide an antitumor agent, which is further excellent as a treatment agent used in the prevention and/or therapy of tumor associated with a bromodomain, and also to provide a bromodomain inhibitor, which is useful as a treatment agent for diseases or states associated with a bromodomain. An antitumor agent and a bromodomain inhibitor, comprising a compound represented by the following formula, have an excellent bromodomain inhibitory activity and are useful as treatment agents in the prevention and/or therapy of tumor associated with a bromodomain, and the like: wherein R1 represents a C1-6 alkyl group, etc.; R2 represents a hydrogen atom, etc.; R3 represents a halogen atom, etc.; Z1, Z2 and Z3 each represent CH, etc.; X1 represents CONH, etc.; Ring A represents a phenyl group, etc.; R4 represents a halogen atom, etc.; and m represents an integer from 0 to 5.
    Type: Application
    Filed: June 26, 2019
    Publication date: October 17, 2019
    Applicants: FUJIFILM Corporation, FUJIFILM Toyama Chemical Co., Ltd., NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY
    Inventors: Keiko MAKITA, Kazunori SAEKI, Tadashi TANAKA, Masataka FUJINO, Tohru NATSUME, Kentaro FURUYA
  • Publication number: 20180296485
    Abstract: An object of the present invention is to provide a liposome and a liposome composition in which release of a drug in blood is suppressed during accumulation of the liposome and the liposome composition in a target site such as a tumor and the drug is rapidly removed after the liposome and the liposome composition are sufficiently accumulated. According to the present invention, there is provided a liposome containing at least a phospholipid to which a hydrophilic polymer is bonded, a phospholipid having a negative charge within a range of a pH of 6 to 8, and a phospholipid which is electrically neutral within a range of a pH of 6 to 8, in which an average carbon chain length of the phospholipid to which the above-described hydrophilic polymer is bonded is shorter than an average carbon chain length of the above-described phospholipid which is electrically neutral within a range of a pH of 6 to 8.
    Type: Application
    Filed: June 20, 2018
    Publication date: October 18, 2018
    Applicant: FUJIFILM Corporation
    Inventors: Naoki YAMADA, Keiko MAKITA, Eriko WATANABE, Takuya INOUE
  • Patent number: 5834293
    Abstract: The invention provides an isolated nucleic acid encoding the rat P450 2C11 arachidonic acid epoxygenase, or a human homologue thereof, having a mutation associated with salt induced hypertension. Also provided is an isolated cell line expressing the epoxygenase encoded by the mutated nucleic acid, and a non-human transgenic animal having a germ line insertion of the mutated nucleic acid. Also provided is a method of screening a compound for efficacy in treating salt induced hypertension comprising administering the compound to such a non-human transgenic animal, and detecting an improvement in the animal's hypertension. The invention also provides a method of screening a human subject for a genetic predisposition to salt induced hypertension comprising detecting a mutation in a human homologue of a rat P450 2C11 arachidonic acid epoxygenase gene which affects normal epoxygenase activity.
    Type: Grant
    Filed: September 28, 1994
    Date of Patent: November 10, 1998
    Assignee: Vanderbilt University
    Inventors: Jorge H. Capdevila, Keiko Makita, Armando Karara